Compare TORM plc (TRMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs State Street SPDR S&P Biotech ETF — how do they compare? TORM plc trades at $28.86 (market cap $2.93B), while State Street SPDR S&P Biotech ETF trades at $158.95. The key difference: TORM plc pays a 9.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TORM plc nearer its low. Which is the better fit depends on your goals.
| TRMD | XBI | |
|---|---|---|
Market Cap | $2.93B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $34.87 | $164.28 |
52-Week Low | $18.77 | $86.92 |
Enterprise Value | $3.82B | — |
Dividend Yield | 9.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $29.04, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI at 24.63. The company reported strong profitability with a 24.41% net margin and ROE of 15.62%, though Q1 2026 EPS missed expectations. Recent news highlights a major shareholder update from Oaktree Capital and a $0.70 dividend payment scheduled for June 2026.
Outlook remains positive with 100% analyst buy ratings, underpinned by robust cash flow and strategic positioning in tanker markets. Risks include earnings volatility and geopolitical impacts on freight rates, but valuation metrics like P/E of 8.4 suggest potential upside if operational execution continues.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
